NIH-funded research R01 grant

Investigating how SGLT2 inhibitors affect heart health in women with HIV

Official title: Effects of SGLT2 Inhibition on Coronary Flow Reserve and Other Key Indices Relevant to Type 2 Myocardial Infarction Risk among Women with HIV

Funded at Massachusetts General Hospital · NIH-11006470 · Data updated 2026-11-12

This study is looking at how a type of medication called SGLT2 inhibitors can help protect the hearts of women living with HIV who are at risk for heart attacks, and it will involve giving some women the medication and others a placebo to see how it affects their heart health.

More Myocardial Infarction research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionMassachusetts General Hospital
NIH-funded
Lab location1 site (Boston, United States)
Project startSeptember 1, 2024
Project endAugust 31, 2029
Funding year2024
Award (this year)$771,613
NIH project number1R01HL170905-01A1
Project IDNIH-11006470 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are women living with HIV who are on antiretroviral therapy and at risk for myocardial infarction.

Less likely to help

Patients who are not living with HIV or those who do not have risk factors for myocardial infarction may not benefit from this research.

What this research studies

This research focuses on women living with HIV who are at a higher risk of heart attacks. It aims to explore how a specific class of medications, known as SGLT2 inhibitors, can improve heart function and reduce risks associated with type 2 myocardial infarction. The study will involve a randomized controlled trial where participants will receive either the medication or a placebo, and their heart health will be monitored using advanced imaging techniques. By understanding the effects of these medications, the research seeks to identify new ways to protect heart health in this vulnerable population.

Why it matters

Potential benefit: If successful, this research could lead to improved heart health and reduced risk of heart attacks for women living with HIV.

How similar studies have gone: Previous research has shown that SGLT2 inhibitors can improve heart function in certain populations, but this specific application in women with HIV is novel.

Where this research is happening

  • Massachusetts General Hospital
    Boston, United States
    Active

Researchers

  • Principal investigator: Zanni, Markella V. — Massachusetts General Hospital
  • Study coordinator: Zanni, Markella V.

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.